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Abstract
Introduction: The quality of Blood Pressure (BP) control remains poor among patients with Chronic Kidney 
Diseases (CKD). It is therefore crucial to develop therapeutic strategies enabling improvement in BP control in order to 
retard the progression of the underlying renal diseases. The cornerstones of therapy include the use of effective and 
well tolerated drugs and a good drug adherence. In this pilot study conducted in ambulant routine care we evaluated 
the potential clinical benefits of implementing a Telemonitoring System (TMS) in parallel to an anticipated change of 
treatment in hypertensive CKD patients with uncontrolled hypertension and/or adverse reactions due to the current 
antihypertensive treatment.
Methods: This is an observational study conducted by 13 Swiss nephrologists in patients with CKD stage III-IV 
and a BP >130/80 mmHg under treatment with an antihypertensive drug. A validated, automated TMS for home BP 
and Heart Rate (HR) monitoring and an electronic scale to measure Body Weight (BW) and a modem to transfer the 
measured parameters to a central database were provided to each patient. The protocol included a run-in phase and 
a drug titration phase of 1 month each and a 2 month maintenance phase. During the titration phase, the calcium 
antagonist lercanidipine could be introduced and up titrated in case of uncontrolled BP.
Results: The use of a TMS in conjunction with the introduction of lercanidipine resulted in a significant reduction 
of office systolic and diastolic BP of respectively -10 ± 21 mmHg (p=0.028) and -5.0 ± 11 mmHg (p=0.049). Home BP 
revealed a parallel significant reduction of -3 ± 1.4 mmHg systolic (p=0.043) and -3 ± 1.2 mmHg (p=0.021) diastolic, 
respectively. The fall in BP was associated with a slight but significant increase in serum creatinine and decrease in 
Estimated Glomerular Filtration Rate (eGFR).
Conclusion: The results of this observational pilot study suggest that a telemonitoring system enabling to follow 
home BP may be useful to improve BP control in hypertensive patients with CKD. However, a prospective randomized 
control study would be needed to assess the real added benefits of this strategy. Administration of lercanidipine in CKD 
patients was effective and well tolerated.
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Introduction
Hypertension is one of the major risk factor for the progression 
of Chronic Kidney Disease (CKD) whatever the origin of the renal 
disease [1]. Although many effective antihypertensive drugs have been 
developed, target BP according to international guidelines (BP <130/80 
mmHg) are reached only in a very small proportion of hypertensive 
patients with diabetes or non-diabetic nephropathies [2,3]. There is 
therefore a strong need to improve the quality of BP control overall, 
and particularly in CKD patients in order to reduce the persisting 
high cardiovascular risk of these patients’ population and to retard the 
progression of their renal disease [4].
Several factors have been identified which may be important to 
improve BP control in CKD as well as in the general hypertensive 
population. These include fighting against the medical inertia, 
monitoring BP outside the physician’s office and supporting long 
term adherence to therapy [5]. These three factors could be markedly 
improved by the use of a Telemonitoring System (TMS) with a 
guidance for the patients on how and when perform ambulant BP 
measurements that provides regular medical information to physicians 
[6-8]. In addition, BP control in hypertensive patients with renal 
insufficiency requires the use of effective antihypertensive treatments 
with favorable renal properties and excellent tolerability including a 
low incidence of edema. Indeed, studies have demonstrated that the 
likelihood that a patient remains under the prescribed therapy depends 
on the tolerability profile of the drugs and on their ability to lower blood 
pressure effectively and rapidly [9]. In this respect, Calcium Channel 
Blockers (CCBs) are recognized as very effective antihypertensive 
therapies, also for patients with renal insufficiency, and trials have 
demonstrated their ability to reduce cardiovascular events [10-13].
However, the efficacy of CCBs is often limited by the occurrence of 
peripheral edema which can affect up to 30% of patients when the CCB 
is given alone or about 20% when combined with a blocker of the Renin-
Angiotensin System (RAS) [10-13]. Lercanidipine is a long acting DHP 
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CCB of the third generation which may be of interest for patients with 
CKD as it demonstrated postglomerular vasodilatory capacities in the 
hypertensive animal [14,15]. In patients with CKD and/or proteinuria 
already treated with a blocker of the RAS, the addition of Lercanidipine 
was found to be effective in lowering BP and proteinuria with a low 
incidence of peripheral edema [16].
The objective of this pilot study conducted by a group of Swiss 
nephrologists was to evaluate the clinical benefits of implementing a 
BP and body weight TMS at the patient’s home to improve BP control 
and monitor the occurrence of edema in patients with chronic kidney 
diseases in conjunction with the administration of lercanidipine.
Patients and Methods
This was a non-interventional, observational, pilot study conducted 
by 13 Swiss nephrologists in patients with CKD and an uncontrolled 
BP. The protocol was approved by the Institutional Review Board of 
Basel.
Male and female hypertensive patients with CKD stage III or IV 
according to the MDRD formula having not achieved a normalized 
BP according to European guidelines (<130/80 mmHg) [3] or 
experiencing adverse drug reactions to antihypertensive treatment 
were enrolled in the study. The study outline is presented in figure 1. 
Once the telemonitoring was installed at the patient’s home, the study 
started with a 1 month run-in phase to evaluate the reliability of the 
system and to obtain the baseline home BP measurements on their 
regular treatment schedule. No change in therapy was planned during 
this phase. At visit 2, home BP data were discussed with the patients, 
confronted to the office BP and Lercanidipine (10-20 mg) could be 
introduced if BP remained above targets (>130/80 mmHg). The dose of 
lercanidipine could be adapted according to home BP during the next 
month (titration phase). If required, doses of other antihypertensive 
drugs when administered in combination with lercanidipine could be 
adapted as well during this treatment phase. Thereafter, patients were 
monitored for another 2 month period (maintenance phase). Office BP 
and a physical examination were performed at each visit.
Telemonitoring 
For the monitoring of home BP, a validated, automated 
Telemonitoring System (TMS; Stabil-O-Graph; Stolberg, Germany) 
[17] was used which enables to monitor BP and heart rate and is also 
combined with a scale to measure Body Weight (BW). Monitoring of 
BW was done in order to investigate the development of subclinical 
edema. The data collected were transferred via a modem to a central 
database. Patients were instructed to measure their BP and HR twice 
a day (morning and evening) and the BW once daily on at least 5 days 
of the week. Participating nephrologists had password protected access 
to the data of their patients. Patients were instructed how to use the 
TMS and to transfer the generated data to the central data base using 
the modem at baseline visit (V1). The TMS featured setting alerts for 
exceeding maximum and/or increased mean values as well as for non-
compliance on agreed measuring intervals.
Anonymous clinical data were collected during routine care visits 
and entered by the nephrologists in an Electronic Data Capture (EDC) 
system and data generated by patients at home using the TMS were 
transferred by a modem to the database. Routine data quality checks 
were performed and clinical data were analyzed using descriptive 
statistics (analysis of variance for repeated measurements and student 
t-tests). Clinical efficacy and safety were evaluated in all patients who 
had a baseline and at least one follow up documentation.
Results
A total of 34 patients were enrolled and started using the TMS. 27 
patients agreed to accomplish a modification of the treatment regimen 
and to continue using the TMS in parallel. Out of the 27 included 
patients, two patients decided to stop using the TMS and two patients 
dropped out during the follow up periods. Thus, 23 patients (85% of the 
included patients) completed the entire program.
Baseline characteristics of patients
The characteristics of the patients are shown in Table 1. Median age 
was 62 years (range: 26 to 83 years) and median body weight was 80 kg 
(range: 52 to 123 kg). The median duration of CKD was 7 years, 37% 
of patients had type 2 diabetes. Moderate proteinuria (< 1g/24h) was 
present in 30% and severe proteinuria (>1g/24h) in 37% of patients. One 
third of patients suffered from a co-morbidity such as obesity, cardiac 
problems, cancer, rheumatic disease or psoriasis. The frequencies of 
antihypertensive treatments administered at start of investigation 
are summarized by substance classes in Table 1. All patients were on 
multiple drug therapies at baseline. Baseline laboratory values and 
renal parameters are shown in Table 1 and Table 2.
Treatments
Individual antihypertensive treatment regimens were changed 
after the run-in period at V2, either due to insufficient efficacy or due to 
adverse events on previous treatments in 80% and 20% of the included 
patients, respectively. Figure 2 shows the proportion of patients 
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Figure 1: Schematic representation of the study protocol.
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treated with each of the 6 antihypertensive classes (CCB, Angiotensin 
Converting Enzyme (ACE) inhibitor, beta-blocker, ARB, and diuretics). 
Lercanidipine was introduced as “add on” or “substitution” in 63% and 
25% of patients, respectively, at a dose of 10 mg or 20 mg in 89% and 
11%, respectively. Thus, the proportion of patients treated with CCBs 
increased from 52% to 89% at V2 (Figure 2), and the proportion of 
patients treated with ACE inhibitor decreased at V2. The proportion 
of patients treated with ARBs remained similar throughout the 
investigation. Additional changes in treatment regimens were recorded 
at FU1 and FU2 visits and titration on administered treatments were 
performed in 89% and 71% of patients at FU1 and FU2 visit. However, 
the average number of drugs per patient recorded at V1 (2.7  ± 1.3) 
remained rather similar at V2 (3.0  ± 1.1) and up to FU2 visit (3.0  ± 
1.2).
Efficacy
Office BP was 147 ± 16 mmHg/87 ± 13 mmHg (mean  ±  SD) at 
baseline (V1). These values decreased significantly with the treatment 
adaptations and further during the use of TMS program to 134 ± 15/80 
± 9 mmHg at FU2 resulting in significant reduction of -10 ± 21 mmHg 
(p=0.028) and -5 ± 11 mmHg (p=0.049) (Figure 3). No relevant change 
in mean HR was observed. At baseline visit, 28% of the patients were 
on a target BP < 140/90 mmHg and only 9% on a target of <130/80 
mmHg according to ESH guidelines. At the FU2 visit, 56% of patients 
achieved a target BP < 140/90 mmHg and 41% achieved the target of 
<130/80 mmHg. 
Home BP measured with the TMS was 134 ± 32/78 ± 19 mmHg 
during the run-in phase; 126 ± 41/73 ± 24 mmHg during the titration 
period and 129 ± 32/73 ± 19 mmHg during the maintenance phase 
(Figure 3). Thus systolic and diastolic BP decreased respectively by -3 
± 1 mmHg (p=0.043) and -3 ± 1 mmHg (p=0.021) between the run-in 
period and the end of the maintenance phase (Figure 3). No significant 
change in heart rate and body weight was observed by means of home 
measurements. A significant increase in serum creatinine (p=0.022) 
and significant decreases in Estimated Glomerular Filtration Rate 
(eGFR) (p=0.047), and a trend for a decrease in creatinine clearance 
(p=0.051) were observed (Table 2).
Tolerability
Adverse drug reactions to lercanidipine were assessed by a 
systematic check list at each visit, while all other Adverse Events (AEs) 
were recorded as spontaneously reported by the patients and analysed 
descriptively (without t-testing). The frequency of peripheral edema 
at baseline, i.e before the anticipated treatment modification, was 35% 
whereas the frequency of edema at FU2, i.e. after the introduction of 
Gender F/M 5/22
Age (years) 58.9 (14.7)
Weight (kg) 83.4 (15.4)
SBP (mmHg) 146.9 (16.3)
DBP (mmHg) 86.9 (12.9)
HR (beats/min) 71.5 (14.4)
Serum creatinine (µmol/l) 202 (95)
eGFR (ml/min/1.73m2) 36 (18)
Diabetics 10 (37%)
Proteinuria
moderate (< 1 g/d) 8 (30%)
severe (> 1 g/d) 10 (37%)
Other co-morbidities 10 (37%)
Administered antihypertensive drugs  (either monotherapy or combination 
therapy)
ACE Inhibitor 10 (37%)
Angiotensin-II-antagonist 17 (63%)
Betablocker 14 (52%)
Calcium antagonist 14 (52%)
Diuretics 19 (70%)
Renin Inhibitor 3 (11%)
Values are means (SD) or actual numbers (%).
NOTE: UNITS SHOULD BE HIGHLIGHTED
Table 1: Clinical characteristics of the included patients.
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Figure 2:  Proportion of patients treated with one or more of the 6 antihypertensive 
classes at baseline, visit of treatment change and follow-up visits (FU1 and FU2).
Baseline (V1) End of follow up (FU2) p=
Serum creatinine 202 (95) Μmol/L 252 (129) µmol/L 0.022
Creatinine clear-
ance 48 (25) mL/min 41 (23) mL/min 0.051
eGFR 36 (18) mL/min/1.73m2 31 (17) mL/min/1.73m2 0.047
Urine Albumine/
creatinine 66 (110) mg/mmol 22 (29) mg/mmol 0.383
Urine Proteine/
creatinine 190 (290) mg/mmol 110 (130) mg/mmol 0.208
Values are means +/- SD 
Table 2: Laboratory values at baseline and at the end of the study.
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Asterisk represents statistically significant changes (p<0.05) compared to V1 
and run-in period, respectively. 
Figure 3: SBP and DBP measured at clinic and at home using telemetry at 
baseline, at V2 (treatment change) and at follow-up visits (FU1 and FU2).
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lercanidipine, was 33%. The frequency of headache and flush showed 
a marked decrease from 29% and 14%, respectively at baseline as 
compared to 16% and 6% at the last visit.
Discussion 
The results of this pilot study indicate that the combined used of a 
TMS enabling to follow home BP together with the use of the calcium 
channel blocker lercanidipine may be useful to improve the treatment 
of hypertension in CKD patients with uncontrolled BP, with 40% 
of patients reaching the target BP during the study. Our study also 
shows that the use of the calcium channel blocker lercanidipine is well 
tolerated with no significant change in body weight under treatment 
and a significant reduction of the incidence of vasodilation-related side 
effects.
The control of hypertension remains low in the general population 
and particularly insufficient in hypertensive patients suffering from 
chronic nephropathies [1,2]. There is therefore a need for improvement 
and new therapeutic strategies have to be developed to improve the 
actual results in order to reduce the incidence of patients reaching 
end-stage renal disease. This pilot study suggests that the combined 
use of a TMS enabling physicians to follow continuously home BP and 
a well tolerated calcium channel blocker may be one way to improve 
BP control in CKD patients. Indeed, the conjunction of the two 
interventions resulted in significant decreases in both, clinic and home 
BP and achieving target BP values in a high proportion of the patients. 
The major limitation of this study is the design that does not enable to 
disentangle the respective role of the TMS and the administration of 
lercanidipine because both interventions were simultaneous. To answer 
this question a more complex study design and a much larger group 
of patients would have been necessary. Recent large controlled studies 
have actually demonstrated the benefits of a TMS in hypertension 
management particularly in patients with uncontrolled BP [7,8].
Nevertheless, our results provide some interesting information for 
practitioners. First, our results confirm that a continuous telemonitoring 
of home BP is feasible and well accepted by patients. Several previous 
studies have demonstrated the clinical benefits of measuring home 
BP using similar concepts in hypertension and heart failure [7,8,18-
20]. Continuous monitoring of home BP has been shown to improve 
BP control in part because it supports drug adherence and because it 
enables rapid medical interventions [6]. As shown in this study, it may 
also be useful for BP monitoring when the antihypertensive treatment 
regimen needs to be optimized. The ability to define alerts for high or 
low BP values may also help to improve the security and the tolerability 
of treatments. Figure 4 illustrates two cases of monitoring with the 
changes in BP.
The significant reductions of systolic and diastolic BP observed in 
our hypertensive patients with renal insufficiency (-10 ± 21 mmHg and 
-5 ± 11 mmHg, respectively), were not as marked as compared to results 
of other clinical studies with lercanidipine [21-26]. However, one has 
to acknowledge that these patients were already heavily treated and 
with a long standing CKD and a reduced renal function. These patients 
are known to be more difficult to control. A subgroup analysis of a 
large observational study using lercanidipine also revealed smaller BP 
reductions in patients with diabetes as compared to the non-diabetics 
[26]. Thus, the fact that 56% and 41% of patients achieved target office 
BP levels of <140/90 mmHg and <130/80 mmHg, respectively can be 
considered as remarkable considering the difficulty to normalize BP in 
this patient’s subgroup.
As expected, BP measurements at home were consistently lower 
than those measured at the clinic and were to some extend within pre-
defined target BP values although one has to remember that according 
to European guidelines home BP targets are lower than office targets 
[3]. Moreover, no prospective study has really defined the home BP 
targets in CKD patients [27]. Our observation also refers to the on-
going discussion on the accuracy of BP measurements during a visit in 
the clinic and on the clinical impact of the “white coat phenomenon”. 
The benefits of home BP measurements have been reviewed recently 
[28]. Importantly, studies have shown that home BP correlates better 
with target organ damages and the risk of cardiovascular events than 
office BP [29,30]. However, the variations in home BP measurements 
were rather high. But, the relatively large number of measurements 
enables to calculate reliable means and standard deviations for 
weekly and/or monthly reports. The high variability of home BP 
measurements has two important clinical consequences: first, patients 
need to be instructed carefully on how to perform the measurements 
in standardized conditions (e.g. performing the measurements always 
at the same morning and evening time, as well as sitting for 3 minutes 
before recording), and second, when using a telemonitoring system 
physicians need to set the alerts at a larger range for a single observation 
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Figure 4:  Representative profiles of two patients: A) Male patient, 61 years 
old B) Male patient, 77 years old. The arrows indicate the date of V2, when 
the anticipated modification of the treatment regimen was performed and V3. 
Profile between arrow 1 and 2 represents the FU1 period while the profile 
right to second arrow represents the period of FU2.
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and to define reasonable ranges for the last 3 to 5 measurements in 
order to avoid unnecessary interventions.
One objective of the study was to investigate the clinical benefits 
of using lercanidipine to lower BP in patients with CKD. Calcium 
channel blockers are very effective in the management of hypertension 
in CKD patients particularly in combination with a RAS blocker [31-
33]. However, the occurrence of peripheral edema is one of the major 
limitation of this antihypertensive class, although the incidence of 
edema is reduced when CCB are administered with RAS blockers. 
Lercanidipine is a third generation dihydropyridine with a high vascular 
selectivity [14]. Its use has been associated with a lower incidence of 
peripheral oedema when compared to nifedipine GITS in a randomized 
double-blind study [34]. In an open-label, switching from a first 
generation CCB to lercanidipine reduces the likelihood of developing 
peripheral edema by approximately 50% [25] and this was confirmed 
in a large observational prospective study published by Burnier et al 
[26]. The overall findings of randomized controlled trials revealed 
that lercanidipine is as effective in lowering blood pressure as other 
CCBs but with particular nephroprotective features and an improved 
tolerability when compared with the first and second generations of 
CCBs. In a randomized, double-blind study in patients with type 2 
diabetes, persistent microalbuminuria and potential risk for diabetic 
nephropathy, lercanidipine, was as effective as ramipril in lowering BP 
and urinary albumin excretion [35]. Therefore lercanidipine may be 
an effective choice for the treatment of hypertension in CKD patients.
The present data tend to confirm the antihypertensive efficacy of 
lercanidipine in CKD patients. Although the individual treatment 
regimens were changed in all included patients to achieve the target BP, 
it is important to point out that the average number of drugs per patient 
remained similar as of the first visit to the last visit indicating that the 
changes in BP are due essentially to the introduction of lercanidipine 
and of the TMS and not to the addition of other antihypertensive agents. 
However, this is not a controlled study and one cannot exclude that 
the adherence to other prescribed treatments has also improved during 
the monitoring leading to a better BP control. Another marker of the 
improved BP control is the increase in serum creatinine and decrease 
in eGFR. These changes very likely reflect the acute renal hemodynamic 
adaptations to the decrease in BP. A similar phenomenon has been 
described in large clinical trials implying the administration of CCB to 
CKD patients [33].
One issue in CKD patients is the incidence of peripheral edema. 
Edema is common in these patients because of the renal disease 
itself and are markedly aggravated by the prescription of CCB. In 
our study, 35% of patients had edema at baseline. In order to assess 
the changes in edema induced by lercanidipine we monitored body 
weight by telemonitoring. No change in body weight was observed 
upon introduction of lercanidipine and the clinical incidence of 
peripheral edema decreased marginally by 2%. Thus, the reduction on 
the incidence of edema in this study was not as marked as observed in 
other studies in non CKD patients [25,26]. Once again, this may reflect 
the impact of the background renal disease. Nevertheless we observed a 
significant reduction of other side effects including headache and flush. 
A similar finding has been reported in a cross-over study when patients 
were switched from another CCB to lercanidipine [25].
In conclusion, the results of this pilot study suggest that a 
telemonitoring system enabling to follow home BP may be useful to 
improve BP control in hypertensive patients with CKD. However, a 
prospective randomized control study would be needed to assess the 
real added benefits of this strategy. Administration of lercanidipine in 
CKD patients was effective and well tolerated.
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